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Lung cancer is the commonest cause of cancer death in developed countries and throughout the world. Cigarette
smoking is the main risk factor for lung cancer and ex-smokers today comprise ∼50% of all new lung cancer
cases. Chemoprevention builds on the concepts of field of cancerization and multistep carcinogenesis and can
be defined as the use of natural or chemical compounds to prevent, inhibit or reverse the process of carcino-
genesis. So far, chemoprevention studies in lung cancer have failed to reduce lung cancer mortality. New develop-
ments in biotechnology have made it possible to define more accurately high-risk populations, make earlier
diagnosis possible, and allow more specific targeted therapies to be developed. Both the development and
validation of biomarkers, for the selection of high-risk study populations and for response evaluation in chemo-
prevention studies, are important for the faster turnover of studies evaluating new agents. This article reviews
the current status and describes the perspectives for new approaches in the chemoprevention of lung cancer.
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Introduction
Lung cancer is the commonest cause of cancer death in developed
countries and throughout the world. Worldwide, the estimated
number of new lung cancer cases in 2002 is 1.2 million (12.3% of
all new cancer cases). Over 90% of these new cases will die as a
result of the disease [1]. The death rate for lung cancer exceeds the
combined total for breast, prostate and colon cancer in developed
countries [1].
Cigarette smoking is the main risk factor for lung cancer,
accounting for ∼90% of cases in men and 70–85% of cases in
women [2]. Genetic risk factors contribute to an individual’s
susceptibility to lung cancer, which is illustrated by the fact that
<16% of long-term smokers will develop lung cancer [3]. Life style
factors (e.g. diet) are also thought to be important in the modu-
lation of risk [3]. Unfortunately, effective clinical tests to assign
risk are lacking. Smoking cessation programs are crucial, but ex-
smokers continue to have a higher risk of developing lung cancer
>40 years after cessation compared with never-smokers [4]. Ex-
smokers comprise nearly 50% of all new lung cancer cases in
developed countries, indicating a strong need for a search for new
means of early diagnosis in lung cancer and chemoprevention in
this high-risk group [4]. However, an important issue for these
approaches is the appropriate selection of an optimal high-risk
population.
In 1993, Sporn pointed out that carcinogenesis is the disease
and not cancer [5]. For comparison, screening and treatment of
cervical dysplasia has led to a remarkable decrease of cervical
cancer incidence and mortality [6]. Premalignant lesions that affect
other organs have been identified and treated (e.g. carcinoma
in situ of the bladder, colon polyps and prostate intraepithelial
neoplasia) [7]. Treatment of these precancerous lesions appears to
be of value for cancer prevention (Table 1).
Chemoprevention trials for lung cancer have been carried out
in phase III clinical trials, studying >70 000 patients for over a
decade with mostly negative results (Table 2) [8–17]. This under-
lines the necessity to find new concepts for chemoprevention
trials in a more cost-effective and time-efficient manner. In the
above-mentioned studies, smoking history has been chosen as
the selection criteria for the study population and lung cancer
incidence or mortality as the end point. According to published
data, smoking history alone might not be selective enough and there
is a need to identify more specific criteria to define the optimal
high-risk study population. Another scientific goal is to validate
intermediate end points in order to achieve short-term studies
that include fewer patients. These concepts are discussed in this
article.
Chemoprevention can be defined as the use of natural or chem-
ically synthesized compounds to prevent, inhibit or reverse the
process of carcinogenesis. Rapid improvement in the understand-
ing of the molecular and biological basis of lung carcinogenesis
raises new possibilities for the chemoprevention of lung cancer.
Combined with advances in endoscopy techniques, such as laser-
induced fluorescence endoscope (LIFE) broncoscopy, and develop-
ments in biotechnology and radiology [18], there are new pos-
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sibilities to diagnose intraepithelial neoplasia and lung cancer at
much earlier stages and new treatment possibilities are emerging
[18].
The chemoprevention principles are built on the concepts of
field of cancerization and multistep carcinogenesis. Field cancer-
ization is characterized by diffuse injury of an epithelial surface as
the result of long-term carcinogenic exposure [19]. Genetic altera-
tion throughout the respiratory epithelium is the result of exposure
to the carcinogens in cigarettes and to radon or other long-term
carcinogenic insults. This ‘preconditioned’ epithelium can give
rise to cancer at multiple points. Studies of the airways of lung
cancer patients show that extensive hyperplasia and dysplasia
occur throughout the bronchial epithelium, accompanied by aneu-
ploidy. These multiple lesions are not usually genetically distinct
from the patient’s tumor and presumably arise independently.
These findings support the idea that the entire upper aerodigestive
Table 1. Chemopreventive agents used in previous studies
NSAID, non-steroidal anti-inflammatory drug.
Mechanisms Agents
Antimutagens Inhibition of carcinogenic metabolites N-Acetyl-cysteine
Reduction of reactive carcinogenic intermediates Dithiole-3-thiones (Oltipraz)
Induction of deactivating phase II enzymes β-Carotenes
Vitamin B12, folic acid
Antiproliferatives Induction of cell differentiation Retinoids
Reduction of growth rate NSAIDs
Induction of apoptosis Glucocorticoids
Inhibition of angiogenesis
Antioxidants Scavenge reactive oxygen species N-Acetyl-cysteine
Scavenge free radicals Vitamin E
Dithiole-3-thiones (Oltipraz)
Table 2. Randomized lung cancer chemoprevention trials with retinoids
aNot significant.
BC, β-carotene; HNC, head and neck cancer; I, primary prevention; II, secondary prevention; III, tertiary prevention; MI, metaplasia index; NAC,              
N-acetylcysteine; NS, not significant (p = 0.44); NSCLC, non-small-cell lung cancer; RA, retinoic acid; RP, retinyl palmitate; RR, relative risk; sputum a., 
sputum atypia; SPT, second primary tumor; Vit.E, vitamin E. 
Trial authors Agents Study group No. of patients End points Effect
[ref.] Treatment Placebo Treatment Placebo (RR; P value)
Trial I No. of lung cancers
ATBC study [8] BC/Vit.E Smokers 14 560 14 573 474 402 Harmful/negative 
(1.18; 0.01)
CARET [9] BC + RA Smokers, 
asbestos
9420 8894 218 170 Harmful 
(1.28; 0.02)
Hennekens et al. [10] BC Smokers 11 036 11 035 1.273 1.293 Negative 
(0.93; 0.65)
Trial II Reduction of sputum atypia
Arnold et al. [11] Etretinate Sputum a. 71 67 NS Negative
McLarty et al. [14] BC + RA Sputum a. 378 377 NS Negative
Decrease in MI
Lee et al. [12] Isotretinoin Metaplasia 41 45 5.1% 10.5%a Negative
Kurie et al. [13] Fenretinide Metaplasia 41 41 7.1%a 4.9% Negative
Trial III SPT
Pastorino et al. [15] RP NSCLC 150 157 18 29 NS
EUROSCAN [16] NAC/RP NSCLC + HNC 1290 1283 115 93 Negative
Lippman et al. [17] Isotretinoin NSCLC 589 577 76 71 Negative
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tract is at risk of developing genetic alterations as a result of
long-term carcinogen exposure. Genetic changes detected in pre-
malignant lesions in one region of the field, translate into an
increased risk of cancer development throughout the entire field.
Contributing factors to the genetic predisposition associated
with increased lung cancer risk are polymorphisms in enzymes
that affect carcinogen activation (P450) and detoxification (glu-
tathione S-transferase), DNA repair genes, inactivation of the p53
tumor suppressor gene and activation of dominant oncogenes. The
interaction of host susceptibility and exposure to carcinogens
leads to variation in cancer susceptibility and presentation.
The concept of multistep carcinogenesis was derived from
pathological observations that mucosal changes in the airways,
including hyperplasia, metaplasia, dysplasia and carcinoma in situ
(CIS), precede or accompany invasive squamous carcinoma [20]
(Figure 1). Hyperplasia, squamous metaplasia and mild dysplasia
have generally been considered as reversible and not premalignant.
Alterations in oncogene and tumor suppressor gene expression
and chromosome structure known to be associated with malignant
transformation are often present in morphologically normal
epithelium of smokers and occur with increasing frequency
through varying degrees of dysplasia to CIS, where they are
universally present.
Chemoprevention studies are based on the hypothesis that inter-
ruption of the biological process involved in carcinogenesis will
reverse or inhibit the carcinogenic process and reduce cancer inci-
dence, and—similar to the approach for other organs—effective
treatment of bronchial dysplasia should reduce lung cancer.
This biological basis of chemoprevention has provided the
framework for the design and evaluation of new chemoprevention
trials. Molecular epidemiological and genotyping risk assessment
models are encouraged to provide a more sensitive and specific
design for the chemoprevention trials. 
The purpose of this article is to review the current status and to
describe the perspectives for new approaches in the chemopreven-
tion of lung cancer.
What did we learn from previous studies?
Retinoids and carotenoids
Consistent evidence suggests that high intake of fruit and veget-
ables are associated with a reduced risk of lung cancer [4]. There-
fore, it has been suggested that micronutrients and macronutrients
present in our diet may act as cancer inhibiting substances. Retin-
oids are natural and synthetic derivatives of vitamin A (retinol).
Carotenoids are a family of conjugated polyene molecules, found
largely in fruit and vegetables, that act as antioxidants; certain
carotenoids also serve as precursors to retinol.
Retinoids are potent regulators of gene expression and signal
their cellular effects through nuclear retinoid receptors. Two classes
of nuclear retinoid receptors—retinoic acid receptor RAR and
retinoid X receptor RXR—have been identified, each of them
having at least three subtypes (α, β and γ, respectively). The
receptors are ligand activated and following the binding to retin-
oids, the retinoid target genes become transcriptionally activated
or repressed. The target genes regulate cell growth, differentiation
and death (apoptosis) [21].
Based on the hypothesis that the reduced risk of lung cancer
associated with a high intake of fruit and vegetables is due to
β-carotene and other antioxidants, epidemiological studies have
verified that intake or serum concentration of β-carotene and
Figure 1. Histology of bronchial epithelium. Grades of dysplasia in bronchial epithelium. (A) Normal two-layered epithelium; (B) squamous metaplasia;   
(C) mild dysplasia; (D) moderate dysplasia; (E) severe dysplasia; (F) carcinoma in situ.
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cancer risk are inversely related [4]. Experimental models together
with these epidemiological data formed the rationale for the use of
retinoids or carotenes in cancer prevention. Added support for a
retinoid-based clinical chemopreventive approach came from the
successful treatment of premalignant lesions (oral leukoplakia,
cervical dysplasia [6] and xeroderma pigmentosum). In addition,
clinical trials have shown that retinoids are active in reducing
some second primary cancers (e.g. second aerodigestive tract
tumors in patients with resected head and neck cancers).
Randomized controlled trials with retinoids
Randomized controlled trials have been conducted in three lung
cancer chemoprevention settings: primary prevention (healthy
high-risk smokers), secondary prevention (premalignant lesions)
and tertiary prevention [second primary tumors (SPT), SPT in
previously treated patients] [8–17] (Table 2).
Three phase III studies were completed involving primary pre-
vention (Table 2): the α-Tocopherol, β-Carotene (ATBC) Study
[8], the β-Carotene and Retinol Efficacy Trial (CARET) [9] and
the Physicians Health Study [10]. In the ATBC trials, the selected
patients were 50–69 years of age and current smokers (five or
more cigarettes per day at entry); in the CARET study, patients
had been exposed to asbestos 15 years before randomization or
were current or former smokers with at least 20 pack-years (pack
years = number of packs cigarettes per day × number of years
smoked). The Physicians Health Study recruited male US phy-
sicians, 40–84 years of age without any history of cancer, myo-
cardial infarction or stroke; only 11% of the study population were
smokers. None of these trials showed a reduction in lung cancer
incidence or mortality. In the ATBC study, 876 new cases of lung
cancer were diagnosed (Table 2), yielding an increased relative
risk of 1.18 among subjects (all of them current smokers) in the
treatment arm. In the CARET study, there were 388 new cases of
lung cancer, yielding an increased relative risk of 1.28 among the
treated patients. Separating the study population in current and
former smokers, the relative risk was increased to 1.42 for current
smokers and decreased to 0.80 for ex-smokers. In the Physicians’
Health Study, 170 new cases of lung cancer were diagnosed, for a
relative risk of 0.93 among men taking β-carotene (non-significant).
The data from these three studies indicated that smokers (current
and ex-smokers analyzed together) who received high-dose
β-carotene supplementation had an increased risk for lung cancer
(the increase in the lung cancer incidence and mortality in the
ATBC study and CARET were 18% and 8%, and 28% and 17%,
respectively).
Four phase IIb trials (Table 2) were conducted in smokers with
metaplasia or sputum atypia for secondary prevention and all
have been negative [11–14]. These trials evaluated α-tocopherol,
β-carotene, retinal, retinyl palmitate or isotretinoin in smokers.
Only smoking cessation correlated with a significant reduction in
squamous metaplasia and cell proliferation [13] and isotretinoin
plus smoking cessation further reduced metaplasia, but so far
neither metaplasia nor sputum atypia are established intermediate
end points for chemoprevention trials.
The consistently positive results of short-term retinoid studies
in head and neck chemoprevention contributed substantially to the
rationale for testing retinoids in lung cancer prevention studies.
There are three available phase III studies [15–17] for tertiary
prevention (Table 2). These studies were designed to determine
whether vitamin A or its analogs could prevent secondary primary
cancers (SPC) in patients with completely resected lung cancers
or head and neck cancers. These patients were previously shown
to have a high risk of SPCs. The two most recent studies [16, 17]
failed to confirm the positive experiences from studies in head–
neck tumors and showed no reductions of SPCs or tumor recur-
rences in contrast to the much smaller preliminary study of
Pastorino et al. [15]. In this small European study, vitamin A
administration improved the time to SPTs but produced no benefit
in terms of overall survival.
So far, all randomized controlled chemoprevention trials testing
retinoids, β-carotenes or α-tocopherol defined their target popu-
lation by using smoking history, preneoplastic changes of the
bronchial epithelium or cancer history. Another critical issue is
the selection of study end points. In primary prevention, lung
cancer incidence and mortality with a long study time has been
the gold standard. In the secondary prevention setting, bronchial
metaplasia or sputum atypia were selected as intermediate end
points, but metaplasia has been reported to be a spontaneously
reversible lesion and neither of them are validated intermediate
end points.
Despite these critical points, the use of retinoids has not been
effective and has possible harmful effects in the chemoprevention
of non-small-cell lung cancer (NSCLC), especially in current
smokers. In order to find an explanation for these results, studies
of the interaction between the products of cigarette smoking and
high blood concentrations of retinoids or β-carotenes have been
performed. For example, the studies of Wang et al. and Liu et al.
showed that ferrets, in the same way as humans, absorb β-carotene
into the bloodstream and transport it to the lungs as well as to
other tissues, whereas mice and rats almost completely convert
β-carotene to retinoids in the intestine and liver and therefore
would transport little to the lungs [22, 23]. The large amounts of
β-carotene in lung tissue in combination with cigarette smoke are
broken down into oxidative metabolites [24, 25]. One possible
explanation of the harm seen in the chemoprevention trials can be
a procarcinogenic effect of the toxic oxidative carotene metab-
olites. But results from Aroro et al. indicate that β-carotene is sen-
sitive to cigarette smoke oxidation but does not lead to prooxidant
effects in human bronchial epithelial cells [26]. They rather have a
direct effect on the nuclear receptors and the retinoid signaling
pathway. The oxidative metabolites induce cytochrome P450
enzymes, lowering the serum levels of retinoid acid and down-
regulating RXR and RARβ. Nicotine by itself inhibits RARβ
expression via methylation and induction of orphan receptor TR3
(a subfamily of transcription factors belonging to the nuclear
receptor superfamily). RARβ is a potent inhibitor of the prolifera-
tion-signaling protein AP-1 and a promoter of apoptosis, so down-
regulation of the different nuclear receptors, as well as defects in
the RA/RARβ-regulated genes, results in retinoic acid resistance
and enhanced mitogenic activities and cell proliferation.
In a study looking at lung precursor lesions in the free resection
margins of patients undergoing surgery for lung cancer or non-
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cancerous diseases, there was a linear increase in the expression of
RXR-α and RXR-χ from never-smokers to dysplasia and in situ
carcinoma and a decrease in RAR-β protein expression from the
first to the last group. Methylation of the RAR-β promoter and
loss of heterozygosity (3p, which contains the gene locus for
RAR-β) are likely to be the important mechanisms.
Several synthetic receptor-selective retinoids have proved to be
more potent than retinoic acid in inhibiting cell growth in lung
cancer models [27]. However, their value in vivo has yet to be
proven in controlled randomized trials. Finally, there are indica-
tions that new routes of administration, such as inhalation, may
provide an effective way of prescribing retinoids [28].
Looking at the side-effects described in randomized trials [8–17],
there was a statistically significant increase in yellowing of the
skin using β-carotenes and dryness of the skin or mucous mem-
branes using retinoids. Other significant treatment-related toxic
effects included arthralgia, nausea or dyspepsia, headache and
hypertriglyceridemia. There is also evidence that a high vitamin A
intake is associated with increased bone fragility and risk of frac-
ture.
Vitamin E (α-tocopherol)
α-Tocopherol (AT) is an antioxidant, scavenging reactive oxygen
species and free radicals, and protecting against oxidative damage.
Similar to carotenes, epidemiological and dietary studies suggest
a potential preventive role for vitamin E [4]. In the only published,
controlled randomized trial—the ATBC study [8]—vitamin E
supplementation had no effect on lung cancer incidence (risk
ratio, 0.99; Table 2). The higher mortality due to hemorrhagic
stroke among the participants who received α-tocopherol was
possibly related to known effects on platelet function. However,
in the same study, there was an association between blood levels
of α-tocopherol and incidence of lung cancer [29]. A 19% reduc-
tion of lung cancer incidence was observed in the highest versus
the lowest quintile of serum α-tocopherol [relative risk, 0.81; 95%
confidence intervals (CI) 0.67–0.97]. α-Tocopherol was found to
be more protective in younger men with fewer years of smoking,
suggesting that high levels of serum α-tocopherol, if present during
the early critical stages of carcinogenesis, may inhibit lung cancer
development.
Selenium
Epidemiological studies suggest that selenium (Se) has anticarcino-
genic capacity and plays a role in cellular defense against oxi-
dative stress [30]; results of these studies have shown an inverse
association between Se status and lung cancer. A recent update
of the Nutrition Prevention of Cancer Trial [31] indicated that Se
supplementation did not significantly decrease lung cancer inci-
dence in the full population, but a decrease among individuals
with baseline plasma selenium in the lowest tertile was observed
(hazard ratio, +0.42; 95% CI 0.18–0.96; P = 0.04). There is an
ongoing randomized phase III trial to determine the effectiveness
of selenium in preventing the development of secondary primary
lung tumors in patients with previously resected stage I NSCLC,
comparing the incidence of specific cancers, mortality from cancer
and overall survival of participants treated with selenium versus
those treated with placebo (ECOG-E5597).
Future directions
New classes of chemopreventive agents
Advances in molecular biology have led to a better understanding
of the important pathways necessary for lung cancer development.
Antibodies and small molecules have been developed to target
specific proteins and block many of these important signaling
pathways, thus leading to a new era of therapeutic possibilities
(Table 3).
The erbB family of receptors [erbB1 (EGFR), erbB2 (HER2/neu),
erbB3 and erbB4] is an important growth factor family of recep-
tors in epithelial cancers. These receptors are activated after ligand
binding and a downstream cascade of biological and physio-
logical reactions occurs. This cascade culminates in cell prolifera-
tion, differentiation and apoptosis [32] (Figure 2). Several classes
of agents block these signaling pathways at different levels [33].
Monoclonal antibodies, such as C225 (Cetuximab; Erbitux®,
Merck KGaA Pharmaceuticals, Darmstadt, Germany), that pre-
vent ligand-dependent activation and small molecules such as
ZD1839 (Gefitinib; Iressa®, AstraZeneca Pharmaceuticals,
Macclesfield, UK) and OSI-774 (Erlotinib; Tarceva®, OSI
Pharmaceuticals, Melville, NY), that selectively inhibit the intra-
cellular tyrosine kinase domain of erbB1 (EGFR), are well tolerated
after chronic administration and have shown regression of
advanced head and neck cancers and NSCLC, even after failure of
multiple chemotherapeutic agents [34].
Immunohistochemical studies of bronchial preneoplasia have
demonstrated significant expression of erbB1 (EGFR) and erbB2
[32] indicating the importance of these growth factor receptors in
lung carcinogenesis. All of the erbB family of receptors hetero-
dimerize with each other [35]. ErbB2 is the preferred heterodimeric
partner for erbB1, erbB3 and erbB4. Such erbB2-containing hetero-
dimers induce potent mitogenic signals. Simultaneous interrup-
tion of both erbB2 and erbB1 is an appealing therapeutic strategy.
Dual erbB1–erbB2 tyrosine kinase inhibitors, such as the small
molecule GW572016, have recently been identified and preclinical
Table 3. List of possible candidates for chemoprevention
EGFR, epidermal growth factor receptor; DFMO, 
difluoromethylornithine; PPARγ, peroxysome proliferator-activated 
receptor gamma; mTOR, mammalian target of rapamycin.
EGFR inhibitors Angiogenesis inhibitors
COX-2 inhibitors Cell-cycle inhibitors
Lipoxygenase inhibitors Proteasome inhibitors
Prostacyclin analogs mTOR inhibitors
Farnesyltransferase inhibitors Protein kinase C inhibitors
Ras inhibitors Demethylation agents
Rexinoids DFMO combination
PPARγ agonists Budenoside
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studies indicate potent inhibition of erbB1 and erbB2, leading to
tumor growth arrest and apoptosis [35]. Clinical data about the
safety and tolerance of these agents must be available before these
drugs can be used in chemoprevention studies.
Activation of the erbB1 leads to downstream ras activation. The
ras gene is mutated in ∼40% of NSCLC cases and this leads to
farnesylation and activation of the ras protein [33]. The farnesyl
transferase inhibitors (FTI) were designed to block ras activation
and the downstream signaling pathway. They also block other
signal proteins that require farnesylation, such as Rho and raf. In
phase I studies, the dose-limiting toxicities of FTIs have been
myelosuppression, neurological complications, nausea, vomiting,
Figure 2. Cell signaling pathways linking epidermal growth factor (EGFR) and cyclooxygenase 2 (COX-2). EGFR activation leads to the initiation of a 
signaling pathway that includes the molecules Grb-2, SOS (Son of Sevenless), Ras, Raf and finally activates mitogen-activated protein kinase (MAPK). This 
results in activation of a group of nuclear transcription factors (c-myc, c-fos, c-jun). They initiate transcription of genes involved in the regulation of cell 
proliferation and differentiation and also induce transcription of COX-2. A second link involves the nuclear transcription factor kappa B (NFκB). EGFR 
ligand binding leads to activation of phosphati-dylinositol-3-kinase (PI3K) which in turn activates the downstream serine/threonine kinase, AKT, promoting 
cell survival. PI3K is involved in the activation of NFκB and the result is increased COX-2 transcription and expression.
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diarrhea and fatigue. Other significant toxicities included skin
sensitivity and rash, but in general, these agents were well toler-
ated at doses that generated pharmacologically significant plasma
concentrations [36].
The eicosanoid pathway
Cyclooxygenase (COX) catalyzes the synthesis of prostaglandins
(PGs) from membrane arachidonic acid (Figure 3). The first step
in the synthesis of PGs is the hydrolysis of phospholipids to pro-
duce free arachidonate, a reaction catalyzed by phospholipase
A2 [37]. Molecular oxygen is then added to arachidonic acid in a
reaction catalyzed by the cyclooxygenase activity of COX. This
reaction produces an unstable product, PGG2. PGG2 is rapidly
converted to PGH2 by the peroxidase activity of COX. PGH2 is the
common precursor for all other prostanoids (e.g. prostaglandins and
thromboxanes), in reactions catalyzed by specific synthetases.
Several of these terminal pathway molecules in the COX and
lipoxygenase (LOX) pathways, such as PGE2 and 5-, 8- and
12-LOX, appear to promote carcinogenesis and metastases, while
other products, such as PGI2, 15-LOX-1 and 15-LOX-2, promote
differentiation and apoptosis.
There are two isoforms of COX, COX-1 and COX-2. COX-1 is
a housekeeping gene, constitutively expressed in most tissues and
mediating normal physiological functions. In contrast, COX-2 is
undetectable in most normal tissues but is induced by inflam-
matory and mitogenic stimuli.
Several lines of evidence suggest that COX-2 is important in
carcinogenesis [38]. First, increased amounts of COX-2 are
commonly found in both premalignant tissues and malignant
tumors, including cancers of the head and neck, esophagus and
lung, reflecting the effects of oncogenes and growth factors [39].
Importantly, wild-type and not mutant p53 suppressed COX-2
transcription. Second, genetic and pharmacological studies showed
extensive evidence that COX-2 is mechanistically linked to the
development of cancer [40]. Third, tobacco specific carcinogens,
such as the β-adrenergic receptor agonist 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone (NNK), releases arachidonic acid, up-
regulates COX-2 expression and stimulates proliferation in lung
adenocarcinoma cell lines [41]. There is also increasing evidence
that nicotine may induce COX-2 expression. COX-2 appears to be
implicated in tumorigenesis in a number of different ways such as
the inhibition of apoptosis and the enhancement of angiogenesis.
It has also been shown that COX inhibitors, such as indomethacin,
contribute positively to the induction of an immune response in
NSCLC. 
The relationship between non-steroidal anti-inflammatory drug
(NSAID) use and lung cancer has been examined in several epidemio-
logical studies. These studies suggest that aspirin and NSAID
ingestion may reduce the risk of developing lung cancer. Pre-
clinical data have shown the chemopreventive effects of NSAIDs
for lung tumorigenesis. In several studies using mouse models,
NSAIDs could prevent the development of lung tumors induced
by tobacco carcinogens by inhibiting COX-2 and by inducing
apoptosis in the premalignant cells. Encouraged by these data,
treatment with COX-2 inhibitors (celecoxib) for chemoprevention
is already under clinical investigation, such as in the NCI-G01-1966
trial, with celecoxib for primary prevention in high-risk tobacco
smokers. Although the question remains: what is the optimal dose
of celecoxib for chemoprevention.
Recent data from transgenic mouse studies at the University of
Colorado Cancer Center indicate that high levels of prostaglandin
synthetase (PGIS), that lead to increased amounts of prostacyclin
(PGI2), result in reduced tumorgenicity in mice exposed to lung
cancer carcinogens (Figure 3). A chemopreventive approach is to
maintain a high level of PGI2 in high-risk patients by giving an
oral PGI2 analog (iloprost). This and related agents are approved
for use in the treatment of several conditions, including throm-
barteritis obliterans, primary pulmonary hypertension and others.
Iloprost is currently under investigation in a phase I/II chemo-
prevention study at the University of Colorado Cancer Center.
The primary objective of that study is to see if iloprost can reverse
premalignant histological changes. The secondary end point is to
examine the effect on the Ki-67 proliferative index.
5-Lipoxygenase (LOX) is a key enzyme in the metabolism of
arachidonic acid to leukotrienes. Increasing evidence suggests
that LOX-catalyzed metabolites have an impact on the develop-
ment and progression of cancers [42]. Compared with normal
tissues, significantly elevated levels of LOX metabolites have
been found in lung, prostate, breast, colon and skin cancers. LOX-
mediated products elicit diverse biological activities important for
neoplastic cell growth, influencing growth factor and transcrip-
tion factor activation, oncogene induction, stimulation of tumor
cell adhesion and regulation of apoptosis. Agents that block LOX’s
catalytic activity may be effective in preventing cancer. Pharmaco-
logical agents inhibiting the LOX-mediated signaling pathways
(e.g. zafirlukast) are already being used in the treatment of inflam-
matory diseases, such as asthma, arthritis and psoriasis. Preclinical
studies have demonstrated that lipoxygenase inhibitors may have
benefits as preventive agents of lung tumorigenesis [43] and should
be studied in human trials.
The combination of COX and LOX inhibitors could also be an
interesting chemopreventive approach. Preclinical data indicated
that inhibition of the COX pathway can be answered with shunt-
ing into the LOX pathway. Interestingly, there are efforts being
made to develop dual inhibitors, able to block both the COX and
LOX metabolic pathways. These dual inhibitors possess a wide
Figure 3. The arachidonic acid pathway. COX, cyclooxygenase; HETE, 
hydroxyeicosatetraenoic acid; HPETE, hydroxyperoxyeicosatetraenoic 
acid; PG, prostaglandin; PL, phospholipase; TXA2, thromboxane A2.
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range of anti-inflammatory and anti-proliferative activity and appear
to be almost exempt from gastric toxicity, which is the most
troublesome side-effect of COX inhibitors [44].
Recent data indicate that COX inhibitors can inhibit signaling
via the EGF receptor (Figure 2). In addition, EGF has been shown
to stimulate COX-2 expression, whereas EGFR and HER2 inhibit-
ors markedly decrease COX-2 activity. A combined blockage of
both pathways (COX-2 and EGFR) has already been studied with
positive results in colon cancer prevention [45]. Such an approach
could also be attractive for lung cancer.
The dithiolethiones are a class of organosulfur compounds,
including oltipraz (5-[2-pyrazinyl]-4-methyl-1,2-dithiol-3-thione)
and anethole dithiolethione (ADT; 5-[p-methoxyphenyl]-1,2-
dithiole-3-thione). Epidemiological studies associate a diet high
in vegetable consumption with a lower risk for many cancers [3].
These vegetables contain many potential cancer-protective sub-
stances including dithiolethiones. In animal models, the adminis-
tration of these compounds protects rodents from the development
of lung and stomach tumors in response to alkylating agents. The
dithiolethiones appear to act via different mechanisms, including
the inhibition of cell replication, and predominantly by increasing
the expression or activity of phase II enzymes, such as glutathione
S-transferase (GST). In addition, ADT increases the intracellular
level of glutathione and displays free radical scavenger properties.
Lam et al. performed a randomized phase IIb study to determine
the effects of ADT in smokers with bronchial dysplasia, identified
by LIFE bronchoscopy [46]. One hundred and twelve current or
former smokers were randomly assigned to receive placebo or
ADT at 25 mg orally thrice daily for 6 months. The primary end
point was response defined by improvement in histology. No
response difference was seen between the two groups. However,
as an undefined end point, the progression rate was statistically
significantly lower in the ADT group (8%) than it was in the
placebo group [17%; P <0.001, difference in progression rate, 9%
(95%CI 4% to 15%)]. This trial suggests that in smokers, ADT is
potentially an effective chemoprevention agent for lung cancer.
This is the first phase IIb lung cancer chemoprevention trial to
use bronchial histology as the primary intermediate end point
biomarker.
From a chemopreventive point of view, the future challenge
is to find the most optimal targeted therapy (or combination of
therapies, Table 3) with respect to the fact that certain require-
ments for feasibility and low toxicity need to be met in such a cate-
gory of patients who are at high risk for developing lung cancer,
but have not yet developed cancer.
Intermediate markers for response evaluation
Considerable research is focusing on the identification of bio-
markers as surrogate or intermediate end points in place of overt
cancer in cancer chemoprevention trials (Table 4). Identification
and validation of such markers is important as it would allow
smaller trials of shorter duration than when using cancer as the end
point. This intermediate biomarker concept is used as well in the
management of other diseases. For example, cholesterol quan-
titation is used to indicate the progression of atherosclerosis as a
surrogate in determining the risk of myocardial infarction.
The use of intermediate biological end points is often referred
to as reversal of premalignancy by successful chemoprevention.
Several requirements need to be fulfilled by a potential inter-
mediate marker: it should be closely involved in the process of
carcinogenesis so that modulation of expression correlates with
the course of the disease; it should have different expression levels
in normal versus preneoplastic tissue and expression/evaluation
Table 4. Lung cancer chemoprevention trials with intermediate biomarkers
aReanalysis of these data found no significant difference between the placebo and treatment groups.
ADT, anethole dithiolethione (5-[p-methoxyphenyl]-1,2-dithiole-3-thione); B12, vitamin B12; BC, β-carotene; hTERT, human telomerase reverse 
transcriptase catalytic subunit.
Trial [ref.] No. of patients Biomarker Intervention 
(versus placebo)
Result
Heimburger et al. [54] 73 Sputum atypia Folate + B12 Increased reversal of atypia in treated subjects 
(P = 0.02)a
Arnold et al. [11] 138 Sputum atypia Etretinate No difference of atypia in treated subjects (P = 0.45)
McLarty et al. [14] 755 Sputum atypia BC + retinol No significant reduction in sputum atypia after
 treatment
Van Poppel et al. [55] 114 Frequency of 
micronuclei in sputum
BC 27% lower micronuclei count in the treatment group
 (95%CI 9% to 41%)
Lee et al. [12] 86 Bronchial metaplasia Isotretinoin No significant metaplasia index change in the
 treatment group (P = 0.37)
Kurie et al. [13] 82 Bronchial metaplasia Fenretinide No significant decrease in metaplasia index
 (P = 0.79)
Lam et al. [46] 112 Bronchial dysplasia ADT No difference in improvement of histology but
significantly lower progression in ADT group 
(8% versus 17%, P <0.001)
Soria et al. [56] 57 Expression hTERT Fenretinide Statistically significant reduction of hTERT
expression in treated subjects (P = 0.01)
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should be easily reproducible. Before integration into routine
use, potential markers need to be validated in prospective clinical
trials.
Promising markers include morphologic changes of the bron-
chial epithelium, as well as cytogenetic and molecular changes.
Research is focusing on intraepithelial neoplasia, a premalignant
condition exemplified by colorectal adenomas or cervical intra-
epithelial neoplasia. To develop a more dependable outcome than
a pathological judgement on a single biopsy, the metaplasia
index—a semiquantitative method to characterize the degree of
metaplasia in a number of bronchial biopsies—has been intro-
duced [47]. The level of metaplastic/dysplastic changes in the
bronchial mucosa seems to be dependent on the selected study
population rather than differences in histopathological interpre-
tation. In a study from the M.D. Anderson Cancer Center (partici-
pants with >20 pack-years and having quit smoking for ≥1 year),
metaplasia was the most prevalent change, while only a few patients
had dysplasia [47]. In a study from the University of Colorado
Cancer Center, >50% of high-risk patients (>30 pack-years,
chronic obstructive pulmonary disease, sputum atypia) had moder-
ate dysplasia or worse [48]. In the latter randomized study, it was
shown that LIFE bronchoscopy improves the detection of preneo-
plastic bronchial lesions significantly compared with traditionally
used white-light bronchoscopy. Thus, the inclusion of LIFE
bronchoscopy is recommended for the evaluation of chemo-
prevention studies.
An intermediate marker for chemoprevention studies of preneo-
plasias must be reproducible. Because metaplasia can spontane-
ously reverse, while dysplasia rarely does, dysplasia should be a
superior intermediate marker for treatment response. Importantly,
morphologic criteria for dysplasia have been defined in the recent
World Health Organization (WHO) classification [20]. This WHO
classification of bronchial preneoplastic changes (Figure 1) has
been found to be highly reproducible by a panel of lung cancer
pathologists [49]. However, more data are needed to determine
the prognostic implications of the different levels of epithelial
changes in the bronchi of high-risk individuals and sparse data are
available for the natural course of the different levels of bronchial
dysplastic changes.
Biological/genetic markers, such as Ki67, MCM2, p53, epithel-
ial growth factor receptor (EGFR) and HER2, have been studied
by immunohistochemistry in bronchial biopsies [50] (Figure 4).
These markers need to be validated as useful intermediate bio-
markers in clinical-pathological studies before they can be routinely
used as intermediate end points for chemoprevention studies.
Furthermore, pathway-specific, ‘downstream’ activated proteins
need to be evaluated as surrogate markers for the biological effect
of the different chemopreventive agents (Figure 2). New markers
are under development, such as microchip gene array and proteo-
mic evaluation of multiple proteins. So far it is too early to predict
their usefulness as intermediate biomarkers in chemoprevention
studies.
Of importance for future studies is the validation of the different
candidates for intermediate biomarkers. Such validation studies
are most properly studied first in nested case–control studies in
untreated high-risk cohorts. Samples for such studies require care-
ful follow-up and a sufficient number of cases (i.e. individuals
who later develop lung cancer) and controls (individuals who do
not develop lung cancer). At the University of Colorado a high-
risk cohort study [>30 pack-years and chronic obstructive lung dis-
ease (COPD)] was started in 1993 and includes >3000 individuals.
Patients with sputum atypia are followed annually with sputum
cytology. Biomarker validation of tumor suppression gene methyl-
ation is currently ongoing in a nested case–control study [51].
Optimal target population for chemoprevention studies
One of the challenges for future studies is to define the optimal
high-risk study population for chemoprevention studies. Different
populations have been studied in primary, secondary and tertiary
chemoprevention studies. The delineation of the optimal high-risk
populations is not well defined but several studies have shown that
it is possible to identify high-risk persons [18]. Most trials selected
the study populations based on smoking history [8, 9, 11–13].
Other studies included risk factors like radon exposure, obstruct-
ive lung disease, prior resected stage I cancer and family history
[3]. Preliminary data from the University of Colorado high-risk
cohort study, including a population with a history of more than
30 pack years and COPD (defined by spirometry), showed an
accumulated risk of developing lung cancer of almost 20% after
10 years [51]. Several studies demonstrated a clear dose–response
relationship between the development of lung cancer and the
degree of exposure to cigarette smoke, measured in pack-years.
However, there is strong evidence that smoking duration and the
age at which smoking began is more important than the number of
cigarettes per day. The relative risk of developing lung cancer
among male smokers with 20 pack-years is 11.59 when they have
smoked 20–29 cigarettes a day (approximately one package) for
20–29 years, but 29.66 when they have smoked 10–19 cigarettes a
day (approximately half a package) for 40 years. These data support
the use of a smoking history of at least 30 pack-years and an
average consumption of at least 20 cigarettes a day to identify
high-risk smokers. Preliminary data from the University of
Colorado high-risk cohort study showed a significantly lower
level of morphological changes in former smokers compared with
current smokers [52].
Another method of defining high-risk smokers is to use inter-
mediate markers, such as preneoplastic changes in the bronchi. In
an autopsy study, sections were taken from the bronchial tree from
445 men who did not die of lung cancer [19]. Advanced histo-
logical changes occurred far less frequently in non-smokers than
in cigarette smokers and increased in frequency with amount of
smoking [19]. However, the relationship between preneoplastic
changes and smoking is most likely dependent on individual
(genetic) factors.
The role of sputum atypia as a risk factor for the detection of
bronchial preneoplasia and development of lung cancer is a sub-
ject currently under investigation. In the Colorado High-risk
Study, 55% of individuals with sputum atypia had high-grade
dysplasia at bronchoscopy [48]. Subjects with moderate or worse
atypia on sputum had an increased odds ratio of 3.2 for developing
lung cancer compared with individuals in the high-risk cohort
without sputum atypia [52]. By adding DNA hypermethylation of
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seven genes in the sputum to the sputum atypia, preliminary data
from 33 cases and 33 controls have shown that the risk increased
to 10.2 [51]. These findings need to be verified in a larger study
population.
Patients who previously had curative treatment for a primary
lung or head and neck cancer have an increased risk of a second
primary cancer of the aerodigestive tract (1–3.4% per year [53]).
These patients are good candidates for intermediate marker-based
chemoprevention studies with histology as a primary end point.
Ongoing chemoprevention studies in this high-risk population
will elucidate the role of several biomarkers as markers for chemo-
preventive effect and/or prediction of outcome. They are also an
excellent group for randomized trials with second cancers as the
primary end point, as described above.
With the development and utilization of low-dose spiral com-
puted tomography for screening and early detection of lung
cancer, new challenges have evolved to characterize the subcen-
timeter small lesions. So far, very little is known about the biology
of these lesions. Many of the detected lesions are characterized as
atypical adenomatous hyperplasia (AAH) and are considered as
premalignant lesions. A chemopreventive treatment approach of
the AAH lesions should be considered when sufficient biological
information is available. However, because these lesions are rela-
tively rare, it seems crucial to establish a registry for patients with
these small lesions, so careful follow-up can give a clinical/
biological profile to distinguish between those patients who
develop invasive cancer and those who do not.
Conclusions
The continuing magnitude and severity of the lung cancer problem
make it imperative to enhance smoking cessation campaigns and
Figure 4. Potential immunohistochemical biomarkers. Immunohistochemistry on paraffin-embedded sections with antibodies for Ki-67, p53, MCM2, EGFR 
and HER2. Marker expression for Ki-67, p53 and MCM2 is the average percentage of cells (in a sample of 400 cells from each biopsy) that express the 
marker. EGFR and HER2 are in these cases evaluated from 0 to 2. Normal bronchial histology have EGFR/HER2 expression mostly in the basal cell layer 
(0), and the expression increase by increased dysplastic changes to half thickness of the epithelium (1+) or expression throughout the full thickness of the 
epithelium (2+).
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to make progress in early detection and chemoprevention. With
the expanded understanding of the molecular and biological
mechanisms of lung cancer development, new specific targets for
prevention are being identified. The identification of appropriate
high-risk patient groups, i.e. a high-risk study population where
more than one in five patients will develop lung cancer, is crucial
and will in the future enable smaller studies to be designed. When
lung cancer incidence is the primary end point, large trials will
accrue subjects over many years. It is important to integrate the
growing biological knowledge in a rational timeframe. The design
of successful chemoprevention trials in the future requires identi-
fication and validation of intermediate end points that are suffi-
ciently predictive of lung cancer development.
Lessons from the treatment of advanced lung cancer and the
increased understanding of important cellular signaling pathways
point out that inhibiting these different regulatory cascades might
prevent/reverse lung carcinogenesis. Because of the complexity
of the signaling network, combinations of targeted therapies
might be an interesting possibility to be tested in chemoprevention
studies. However, it is important that such studies are well
designed in order to gather as much clinical/biological informa-
tion as possible for future chemoprevention studies.
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